Free Trial

UroGen Pharma (URGN) Earnings Date, Estimates & Call Transcripts

UroGen Pharma logo
$11.19 -0.67 (-5.65%)
(As of 11/15/2024 ET)

UroGen Pharma Latest Earnings Summary

Upcoming Q4
Earnings Date
Mar. 13Estimated
Actual EPS
(Nov. 6)
-$0.55 Beat By $0.29
Consensus EPS
(Nov. 6)
-$0.84

UroGen Pharma announced Q3 2024 earnings on November 6, 2024, reporting an EPS of -$0.55, which beat analysts' consensus estimates of -$0.84 by $0.29. Quarterly revenue was reported to be $25.20 million, above analyst estimates of $24.22 million. With a trailing EPS of -$3.15, UroGen Pharma's earnings are expected to grow next year, from ($3.10) to ($2.85) per share.

URGN Upcoming Earnings

UroGen Pharma's next earnings date is estimated for Thursday, March 13, 2025, based off prior year's reporting schedules.

Get UroGen Pharma Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on UroGen Pharma and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

URGN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

URGN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

UroGen Pharma Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241-$0.94-$0.94-$0.94
Q2 20241-$0.77-$0.77-$0.77
Q3 20241-$0.80-$0.80-$0.80
Q4 20241-$0.65-$0.65-$0.65
FY 20244-$3.16-$3.16-$3.16
Q1 20251-$0.83-$0.83-$0.83
Q2 20251-$0.79-$0.79-$0.79
Q3 20251-$0.74-$0.74-$0.74
Q4 20251-$0.70-$0.70-$0.70
FY 20254($3.06)($3.06)($3.06)

UroGen Pharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks
3/13/2025
(Estimated)
------- 
11/6/2024Q3 2024-$0.84-$0.55+$0.29-$0.55$24.22M$25.20M    
8/13/2024Q2 2024-$0.82-$0.91 -$0.09-$0.91$23.69M$21.85M
5/13/2024Q1 2024-$0.93-$0.97 -$0.04-$0.97$20.73M$18.78M  
3/14/2024Q4 2023-$0.67-$0.72 -$0.05-$0.72$22.30M$23.53M      
11/14/2023Q3 2023-$0.89-$0.68+$0.21-$0.68$19.80M$20.85M  
8/10/2023Q2 2023-$1.13-$1.03+$0.10-$1.03$19.90M$21.14M  
5/11/2023Q1 2023-$1.39-$1.30+$0.09-$1.30$16.55M$17.19M  
3/16/2023Q4 2022-$1.12-$1.22 -$0.10-$1.22$18.25M$18.09M  

UroGen Pharma Earnings - Frequently Asked Questions

UroGen Pharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 13th, 2025 based off last year's report dates. Learn more on URGN's earnings history.

In the previous quarter, UroGen Pharma (NASDAQ:URGN) reported ($0.55) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.84) by $0.29. Learn more on analysts' earnings estimate vs. URGN's actual earnings.

The conference call for UroGen Pharma's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for UroGen Pharma's latest earnings report can be read online.
Read Transcript

UroGen Pharma (NASDAQ:URGN) has a recorded annual revenue of $82.71 million.

UroGen Pharma (NASDAQ:URGN) has a recorded net income of -$102.24 million. URGN has generated -$3.15 earnings per share over the last four quarters.

UroGen Pharma's earnings are expected to grow from ($3.10) per share to ($2.85) per share in the next year.

`

More Earnings Resources from MarketBeat



This page (NASDAQ:URGN) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners